Cite
Switching to Doravirine in cART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost Savings.
MLA
Lanting, Vincent R., et al. “Switching to Doravirine in CART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost Savings.” JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 95, no. 2, Feb. 2024, pp. 190–96. EBSCOhost, https://doi.org/10.1097/qai.0000000000003337.
APA
Lanting, V. R., Oosterhof, P., Ait Moha, D., van Heerde, R., Kleene, M. J. T., Stalenhoef, J. E., de Regt, M. J. A., Vrouenraets, S. M. E., van den Berk, G. E. L., & Brinkman, K. (2024). Switching to Doravirine in cART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost Savings. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 95(2), 190–196. https://doi.org/10.1097/qai.0000000000003337
Chicago
Lanting, Vincent R., Piter Oosterhof, Daoud Ait Moha, Roos van Heerde, Marie José T. Kleene, Janneke E. Stalenhoef, Marieke J. A. de Regt, Saskia M. E. Vrouenraets, Guido E. L. van den Berk, and Kees Brinkman. 2024. “Switching to Doravirine in CART-Experienced Patients: An Effective and Highly Tolerated Option With Substantial Cost Savings.” JAIDS: Journal of Acquired Immune Deficiency Syndromes 95 (2): 190–96. doi:10.1097/qai.0000000000003337.